• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Supernus Pharmaceuticals, Inc. (SUPN) Stock Price, News & Analysis

Supernus Pharmaceuticals, Inc. (SUPN) Stock Price, News & Analysis

Currency in USD Disclaimer

$35.80

-$0.32

(-0.89%)

Day's range
$35.54
Day's range
$36.53
50-day range
$29.74
Day's range
$39.37
  • Country: US
  • ISIN: US8684591089
52 wk range
$25.53
Day's range
$39.37


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 5.06
  • Piotroski Score 6.00
  • Grade Overweight
  • Symbol (SUPN)
  • Company Supernus Pharmaceuticals, Inc.
  • Price $35.80
  • Changes Percentage (-0.89%)
  • Change -$0.32
  • Day Low $35.54
  • Day High $36.53
  • Year High $39.37

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $38.00
  • High Stock Price Target $40.00
  • Low Stock Price Target $36.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.29
  • Trailing P/E Ratio -90.55
  • Forward P/E Ratio -90.55
  • P/E Growth -90.55
  • Net Income $1.32 M

Income Statement

Quarterly

Annual

Latest News of SUPN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Supernus Pharmaceuticals, Inc. Frequently Asked Questions

  • What were the earnings of SUPN in the last quarter?

    In the last quarter Supernus Pharmaceuticals, Inc. earnings were on Monday, November, 4th. The Supernus Pharmaceuticals, Inc. maker reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.39 by $0.67.

  • What is the Supernus Pharmaceuticals, Inc. stock price today?

    Today's price of Supernus Pharmaceuticals, Inc. is $35.80 — it has decreased by -0.89% in the past 24 hours. Watch Supernus Pharmaceuticals, Inc. stock price performance more closely on the chart.

  • Does Supernus Pharmaceuticals, Inc. release reports?

    Yes, you can track Supernus Pharmaceuticals, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Supernus Pharmaceuticals, Inc. stock forecast?

    Watch the Supernus Pharmaceuticals, Inc. chart and read a more detailed Supernus Pharmaceuticals, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Supernus Pharmaceuticals, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Supernus Pharmaceuticals, Inc. stock ticker.

  • How to buy Supernus Pharmaceuticals, Inc. stocks?

    Like other stocks, SUPN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Supernus Pharmaceuticals, Inc.'s EBITDA?

    Supernus Pharmaceuticals, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Supernus Pharmaceuticals, Inc.’s financial statements.

  • What is the Supernus Pharmaceuticals, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0.0021661803, which equates to approximately 0.22%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Supernus Pharmaceuticals, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Supernus Pharmaceuticals, Inc.'s financials relevant news, and technical analysis. Supernus Pharmaceuticals, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Supernus Pharmaceuticals, Inc. stock currently indicates a “sell” signal. For more insights, review Supernus Pharmaceuticals, Inc.’s technical analysis.

  • A revenue figure for Supernus Pharmaceuticals, Inc. for its last quarter?

    Supernus Pharmaceuticals, Inc. published it's last quarterly revenues at $175.69 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.